Joanne S. Eglovitch
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Joanne S. Eglovitch
Industry groups PDA and ISPE have banded together to produce a guide to help pharmaceutical manufacturers get a better handle on their deviations through choosing the right root cause analysis method and human factors studies.
Industry is still having major problems in this area despite the FDA's exhaustive 2006 OOS guidance.
To reduce false alarms of counterfeits, EU tells drugmakers no lowercase, hyphens, question marks or certain letters in serial and batch numbers.
Agency demands review of invalidated out-of-specification findings as root causes of failures continue to elude Indian drugmaker at multiple facilities.
FDA official tells generics firms how to avoid letting excipient filing mistakes prompt ANDA derailments via refuse-to-receive letters.
The US FDA announces plans to expand its new protocol-based approach to inspections, NIPP, to non-sterile drugs and provides glimpse of what metrics the agency is using to measure pharmaceutical quality during inspections.